White Paper

Creating A Sustainable Business Model For Cell And Gene Therapies


Stock-market weakness during 2022 and early 2023, as central banks have raised rates to combat inflation, has put pressure on startups to deliver results. In the biomedical field, innovators need to think more carefully about their strategies for developing and commercializing new therapies. The path to success for businesses involved in cell and gene therapy is not without challenges. Unlike other areas of pharmaceuticals, in this field 90% of companies are still trying to launch their first product.

To examine how the development of cell and gene therapies can be made a sustainable business, Economist Impact facilitated a roundtable discussion, supported by AmerisourceBergen, as part of the Cell and Gene Therapy Summit 2023. Participants included senior staff in the biopharmaceutical industry, clinicians, academics and researchers, and members of patient-advocacy organizations.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader